巴瑞替尼治疗活动性类风湿关节炎临床试验中的感染分析
该分析基于8项临床研究和1项长期扩展研究,纳入3492例接受巴瑞替尼治疗的活动性类风湿关节炎患者,累计7860患者年暴露。结果显示巴瑞替尼治疗出现感染(包括带状疱疹)的发生率高于安慰剂,严重感染率与安慰剂相似且随时间稳定,结核和机会性感染罕见。
要点
- 巴瑞替尼治疗出现感染发生率高于安慰剂,4mg组差异有统计学意义。
- 严重感染发生率与安慰剂相似,all-bari-RA为3.0/100患者年。
- 带状疱疹发生率高于安慰剂,4mg组差异有统计学意义。
核心结论
- 活动性类风湿关节炎患者接受巴瑞替尼治疗时,治疗出现感染(包括带状疱疹)的发生率升高,与其免疫调节作用机制一致。
研究设计与样本
- 基于整合数据库(8项3/2/1b期临床试验和1项长期扩展研究),数据截至2017年4月1日。
- all-bari-RA分析集纳入接受任何巴瑞替尼剂量的患者;安慰剂对照基于6项研究至第24周,包括4项含2mg的研究;剂量反应评估基于4项含2mg和4mg的研究(含长期扩展数据)。
主要发现
- 3492例患者接受巴瑞替尼治疗,累计暴露7860患者年(中位2.6年,最长6.1年)。
- 治疗出现感染发生率:安慰剂75.9/100患者年,2mg组84.0/100患者年(p无显著性),4mg组88.4/100患者年(p≤0.001)。
- 严重感染发生率与安慰剂相似且随时间稳定,all-bari-RA为3.0/100患者年。
- 结核共11例(all-bari-RA发生率0.1/100患者年),均发生在流行地区的4mg组。
- 带状疱疹发生率:安慰剂1.0/100患者年,2mg组3.1/100患者年(p无显著性),4mg组4.3/100患者年(p≤0.01);all-bari-RA为3.3/100患者年且随时间稳定;机会性感染(包括多皮节带状疱疹)少见(all-bari-RA发生率0.5/100患者年)。
关键数值与推荐
- 治疗出现感染发生率:安慰剂75.9/100患者年,巴瑞替尼2mg组84.0/100患者年(p无显著性),4mg组88.4/100患者年(p≤0.001)。
- 带状疱疹发生率:安慰剂1.0/100患者年,2mg组3.1/100患者年(p无显著性),4mg组4.3/100患者年(p≤0.01)。
- 严重感染发生率:all-bari-RA为3.0/100患者年。
- 结核发生率:all-bari-RA为0.1/100患者年,11例均发生在流行地区的4mg组。
- 机会性感染发生率:all-bari-RA为0.5/100患者年。
临床怎么用
- 使用巴瑞替尼治疗活动性类风湿关节炎时,应关注感染风险,尤其是带状疱疹,4mg剂量组风险更高。
- 在结核流行地区使用4mg巴瑞替尼时,需警惕结核感染风险。
- 严重感染发生率与安慰剂相似且长期稳定,但仍需在治疗中监测感染迹象。
局限性
- 数据截至2017年4月1日,长期安全性数据有限。
- 安慰剂对照仅至第24周,长期比较依赖长期扩展研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the incidence of infection in patients with active rheumatoid arthritis (RA) treated with baricitinib, an oral selective Janus kinase (JAK)1 and JAK2 inhibitor. METHODS: Infections are summarised from an integrated database (8 phase 3/2/1b clinical trials and 1 long-term extension (LTE)) with data to 1 April 2017. The 'all-bari-RA' analysis set included patients who received any baricitinib dose. Placebo comparison was based on six studies with 4 mg and placebo to week 24, including four trials with 2 mg (placebo-controlled set). Dose-response assessment was based on four studies with 2 mg and 4 mg, including LTE data (2-4 mg extended set). RESULTS: There were 3492 patients who received baricitinib for 7860 patient-years (PY) of exposure (median 2.6 years, maximum 6.1 years). Treatment-emergent infections were higher for baricitinib versus placebo (exposure-adjusted incidence rate (IR)/100 PY: placebo 75.9, 2 mg 84.0 (p not significant), 4 mg 88.4 (p≤0.001)). The IR of serious infection was similar for baricitinib versus placebo and stable over time (all-bari-RA IR 3.0/100 PY). There were 11 cases of tuberculosis (all-bari-RA IR 0.1/100 PY); all occurred with 4 mg in endemic regions. Herpes zoster (HZ) IR/100 PY was higher for baricitinib versus placebo (placebo 1.0, 2 mg 3.1 (p not significant), 4 mg 4.3 (p≤0.01)); rates remained elevated and stable over time (all-bari-RA 3.3). Opportunistic infections, including multidermatomal HZ, were infrequent in the baricitinib programme (all-bari-RA IR 0.5/100 PY). CONCLUSIONS: Increased rates of treatment-emergent infections including HZ were observed in patients with RA treated with baricitinib, consistent with baricitinib's immunomodulatory mode of action.
引用
- Winthrop KL, Harigai M, Genovese MC, et al. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis. 2020. PMID: 32788396. doi:10.1136/annrheumdis-2019-216852
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。